Unknown

Dataset Information

0

Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1- CD4+ T cells.


ABSTRACT: BCG, the only vaccine licensed against tuberculosis, demonstrates variable efficacy in humans. Recent preclinical studies highlight the potential for mucosal BCG vaccination to improve protection. Lung tissue-resident memory T cells reside within the parenchyma, potentially playing an important role in protective immunity to tuberculosis. We hypothesised that mucosal BCG vaccination may enhance generation of lung tissue-resident T cells, affording improved protection against Mycobacterium tuberculosis. In a mouse model, mucosal intranasal (IN) BCG vaccination conferred superior protection in the lungs compared to the systemic intradermal (ID) route. Intravascular staining allowed discrimination of lung tissue-resident CD4+ T cells from those in the lung vasculature, revealing that mucosal vaccination resulted in an increased frequency of antigen-specific tissue-resident CD4+ T cells compared to systemic vaccination. Tissue-resident CD4+ T cells induced by mucosal BCG displayed enhanced proliferative capacity compared to lung vascular and splenic CD4+ T cells. Only mucosal BCG induced antigen-specific tissue-resident T cells expressing a PD-1+ KLRG1- cell-surface phenotype. These cells constitute a BCG-induced population which may be responsible for the enhanced protection observed with IN vaccination. We demonstrate that mucosal BCG vaccination significantly improves protection over systemic BCG and this correlates with a novel population of BCG-induced lung tissue-resident CD4+ T cells.

SUBMITTER: Bull NC 

PROVIDER: S-EPMC7051908 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1<sup>+</sup> KLRG1<sup>-</sup> CD4<sup>+</sup> T cells.

Bull N C NC   Stylianou E E   Kaveh D A DA   Pinpathomrat N N   Pasricha J J   Harrington-Kandt R R   Garcia-Pelayo M C MC   Hogarth P J PJ   McShane H H  

Mucosal immunology 20181116 2


BCG, the only vaccine licensed against tuberculosis, demonstrates variable efficacy in humans. Recent preclinical studies highlight the potential for mucosal BCG vaccination to improve protection. Lung tissue-resident memory T cells reside within the parenchyma, potentially playing an important role in protective immunity to tuberculosis. We hypothesised that mucosal BCG vaccination may enhance generation of lung tissue-resident T cells, affording improved protection against Mycobacterium tuberc  ...[more]

Similar Datasets

| S-EPMC5417795 | biostudies-literature
| S-EPMC10594996 | biostudies-literature
| S-EPMC5120139 | biostudies-literature
| S-EPMC4548053 | biostudies-literature
| S-EPMC4529167 | biostudies-literature
| S-EPMC9043212 | biostudies-literature
2015-06-19 | E-GEOD-69998 | biostudies-arrayexpress
| S-EPMC344011 | biostudies-other
| S-EPMC10788536 | biostudies-literature
| S-EPMC5461001 | biostudies-literature